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The recent discoveries of broadly potent neutralizing human monoclonal antibodies rep-
resent a new generation of antiretrovirals for the treatment and prophylaxis. Antibodies 
are generally considered more effective and safer and have been proved to provide pas-
sive protection against mucosal challenge in humanized mice and macaques. Several 
neutralizing Abs could protect animals against HIV-1 but are not effective when used in 
an established infected model for therapy. In order to overcome the limitation of antiviral 
activities, multiple antibody-engineering technologies have been explored to generate 
“the better” neutralizing antibodies against HIV-1 since bNAbs attack viral entry by 
various mechanisms. Thus, a promising direction of research is to discover and exploit 
rational antibody combination or engineered antibodies (eAbs) as potential candidate 
therapeutics against HIV-1. It has been reported that inclusion of fusion- neutralizing anti-
bodies in a set of bNAbs could improve their overall activities and neutralizing spectrum. 
Here, we review several routes for engineering bNAbs, such as design and generation 
of bispecific antibodies, specific glycosylation of antibodies to enhance antiviral activity, 
and variable region-specific modification guided by structure and computer, as well as 
reviewing antibody-delivery technologies by non-viral vector, viral vector, and human 
hematopoietic stem/progenitor cells transduced with a lentiviral construct. We also 
discuss the optimized antiviral activities and benefits of these strategy and potential 
mechanisms.
Keywords: Hiv-1 neutralizing antibodies, antibody engineering, bispecific antibody, variable region, antigen 
binding, gene delivery
iNTRODUCTiON
Currently, through single memory B-cell sorting from HIV-1-infected patients and micro-
neutralization screening of B-cell cultures, many new monoclonal antibodies (mAbs) have been 
isolated and characterized successfully, such as VRC01, PG9, 3BCN117, NIH45–46, PGT Abs, 
and 10E8 (1–5). Previously, it was a concern that an increase in the antiviral breadth may be 
accompanied by a loss in neutralizing activity, but new broadly neutralizing antibody (bNAbs) 
can offer potent and broad neutralization of diverse HIV-1 isolates (6). These discoveries have led 
to further optimism that effective vaccines against HIV-1 will be discovered, especially those that 
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induce cross-clade neutralizing antibodies (7). However, how to 
translate the new knowledge about neutralizing epitopes into 
immunogens that elicit potent and persistent immunity is still 
a challenge (8).
Since the new-generation antibodies exhibit a sufficient level 
of breadth in their ability to neutralize genetically diverse HIV-1 
strains, as an alternative approach, passive immunization using 
broadly neutralizing antibodies can be applied for immunization 
and therapy for HIV-1. Several broadly neutralizing mAbs have 
been shown to protect against HIV-1 infection in animal models 
when administered as monotherapy (9–12). However, as a threat, 
viral resistance is still present in HIV-1 clinical therapeutics, and 
HIV-1 has been shown to develop resistance to neutralizing anti-
bodies as well. By now, it has been reported that antiviral activity 
of new-generation neutralizing antibodies in treating an estab-
lished HIV-1 infection is limited (10, 11, 13–15). Particularly, 
viral load rebounds quickly in all infected patients treating either 
high or low doses of neutralizing therapeutic antibody due to the 
outgrowth of pre-existing or de novo viral escape variants. Thus, 
it is very difficult for antibodies to eliminate the virus and virus-
infected cells in vivo once the resistant mutants rapidly emerge.
On the other hand, there is no cross-resistance with the cur-
rently feasible antiretroviral to give their distinct mechanisms 
of antiviral action. It has been reported that combining several 
different antiviral mechanism’s neutralizing antibodies would 
increase the barrier against resistance in  vivo than any one 
antibody alone (10, 11, 13, 16–18). Thus, novel broadly potent 
neutralizing antibodies are needed to deter the development of 
HIV-1 resistance.
Parent neutralizing antibodies can be engineered to improve 
their antigen-binding affinity, effect functions, improve their 
half life, and apply new delivery methods in  vivo. Thanks to 
advances in antibody-engineering technology (19, 20), such as 
variable-region modification, modification of the glycosyla-
tion pattern, and design of bispecific antibody (bsAb) formats, 
it has been possible to create novel optimized mAbs that may 
improve the antiviral activity of bNAbs or target multiple viral 
epitopes to overcome neutralization escape by potency and 
breadth improvement. In addition, using viral vectors or non-
viral vector-mediated technology to deliver the antibodies into 
circulation, or even implantation of an HIV-specific bNAb gene 
into hematopoietic stem/progenitor cells (HSPCs), can provide 
anti-HIV mucosal immunity by effectively reprogramming the 
immune system. These new platforms for engineering antibodies 
make HIV-1-neutralizing antibodies more available as candidate 
therapeutics against this virus.
BROADLY NeUTRALiZiNG ANTiBODieS 
AGAiNST Hiv-1
HIV-1 entry into cell is triggered by interaction of the viral 
trimeric envelope (Env) glycoprotein gp120 with CD4 in T cell 
surface (21, 22). The key steps include (A) binding of gp120 to its 
receptor CD4 on T helper cells, with the formation and exposure 
of the coreceptor (CoR)-binding site in gp120; (B) binding of the 
HIV-1’s gp120 to CoRs (CCR5 or CXCR4); (C) fusion of the viral 
and host cellular membranes (21, 23). Therefore, HIV-1 infection 
elicits specific antibody against both gp120, gp41 of the Env and 
conformational epitopes induced by trimmer. Meanwhile, viral 
entry makes targets available for new-generation neutralizing 
antibodies to inhibit HIV-1 infection (Figure 1).
Broad and potent anti-HIV-1 neutralizing mAbs can inhibit 
entry of the virus into the host cell by various mechanisms. One 
mechanism is interfering with the attachment of the virus to host 
cell surface receptors. This can be achieved when the antibody 
binds to gp120 on HIV-1 spikes, thereby interfering with the 
binding of the virus’s gp120 to the host cell’s CD4 (24). The same 
inhibitory effect is achieved by antibodies targeting T cell receptor 
CD4 or CoRs, such as CCR5 and CXCR4, thereby interfering with 
virus interaction with cell membrane or blocking the receptor 
binding sites for the virus unavailable, resulted in against HIV-1 
entry (25). Another neutralizing mechanism is post-attachment/
pre-fusion neutralization and interference with gp120-required 
conformational changes and fusion processes at the target cell 
membrane.
Several specific sites on gp120 have been shown to be tar-
geted by bNAbs. (A) The CD4-binding site (CD4bs) on gp120 
is recognized by a number of broadly neutralizing mAbs. These 
Abs include VRC01, NIH45–46, 12A12, and 3BNC117 (1, 4, 8, 
26–28), which neutralize 80–90% of circulating HIV-1 isolates 
with high potency in  vitro, as well as CH103 and 8ANC131 
with relatively less potency; (B) the V1V2 site has been proven 
to be another site of the spike that is vulnerable to neutralizing 
antibodies. PG9, PG16, and PGDM1004 are representatives of 
V1V2-directed neutralizing mAbs that generally compete with 
one another for antigen (29–31); (C) N-linked glycan-containing 
epitopes form a site of spike vulnerability, including the gp120 
V3 loop, and several nearby glycans, 2G12, PGT128, and 
PGT121/10-1074 represent the bNAbs that recognize this region 
(2, 32, 33); (D) there are also bNAbs that target the coreceptor-
binding site (CoRbs) on gp120. The exposure of this site, also 
known as the CD4-induced (CD4i) site, is (as its name suggests) 
induced by conformational changes that occur as a result of the 
binding of CD4 to gp120. Antibodies targeting this region are 
called CD4-induced antibodies, and include 17b, X5, m36, 48d, 
and E51 (34–36). Based on the length of the IgG heavy chain 
CDR, most full-size CD4i Abs do not have high antiviral potency 
because full-size Abs targeting CD4i-specific epitope is sterically 
restricted during viral entry (37).
The membrane-proximal external region (MPER) of gp41 
contains highly conserved residues that also play a critical role 
in the virus fusion process. Only 671–683 AA as a linear epitopes 
of this MPER are recognized by potent neutralizing mAbs (38, 
39). These bNAbs include 4E10, 2F5, Z13, and 10E8 (3, 40, 41). 
Although previous studies show that combination of 2F5 and 
10E8 protects rhesus against SIV infection, 10E8 still exhibits 
most potent and broad neutralizing activity compare with other 
MERP active antibody targeting gp41 of HIV-1. It can neutralize 
about 92% of circulating HIV-1 isolates in vitro.
Ibalizumab (iMab) is a mAb that has broad and potent activity 
against HIV-1; it inhibits HIV-1 by binding mainly to domain 2 
(D2) of CD4 on host target cells, inhibiting post-CD4 binding 
events required to infect cells (42). PRO-140 is a monoclonal 
antibody directed against the CCR5 CoR (CCR5 antagonists), 
FiGURe 1 | Schematic interactions between Hiv-1 and a T cell in the presence of broadly neutralizing antibodies (bNAbs).
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and it potently inhibits CCR5-mediated HIV-1 entry without 
blocking the natural activity of CCR5 in vitro (43).
Almost all of the potent neutralizing antibodies have some 
unusual features. The CD4-specific antibodies exhibit unusual 
maturation with somatic maturation frequencies of 20–32%. The 
V1V2-specific antibodies display unusually long CDRH3 of 24–32 
amino acid. The V3 glycan-specific antibodies show a relatively 
high somatic mutation CDR H3s with deletions or insertions. The 
gp41’s MPER-specific antibodies display relatively high somatic 
mutation. Understanding the targeting sites, inhibition activities, 
and unusual feature of above antibodies will contribute to genera-
tion of more potent neutralizers by antibody engineering.
Hiv-1 NeUTRALiZiNG ANTiBODY 
eNGiNeeRiNG
As we know, the Env-targeted antibodies comprise mainly of 
binding antibodies without neutralizing activity or strain-specific 
antibodies after HIV-1 infection or HIV-1 vaccine immuniza-
tion. The hurdles of neutralizing antibody generation against 
HIV-1 are mainly caused by conformational mask and diversity 
of HIV-1 strains. The new-generation bNAbs, being applied 
for therapy, also faced the limitation of antiviral breadth and 
potency. Thus, antibody engineering might provide a potential 
approach to overcome the limitation. The primary role of the 
antibody’s variable region is to bind to the specific antigen or 
epitope, resulting in neutralization against HIV-1. The affinity 
and the specificity of the mAb are two important antigen-binding 
properties, and engineering these properties has been extensively 
studied recently to improve the effectiveness of HIV-1 neutral-
izing antibodies. Meanwhile, new strategies are currently focused 
on adding more functionality to existing mAbs. That is, there are 
a variety of strategies being undertaken to enhance the antiviral 
properties of mAbs.
Bispecific Antibody Design and 
Mechanism
At present, although using monotherapy by neutralizing 
antibodies can protect against HIV-1 infection in animal 
models, the efficacy in administrating an established infection 
is not satisfied. One of the reasons is that HIV-1 strains’ RNA 
polymerases are devoid of proofreading and repair capabilities, 
resulting in the emergence of resistant mutants under neutral-
izing antibody selective pressure. Furthermore, several viruses 
treated with a non-specific antibody have been shown to 
generate the mutated residues associated with viral escape, 
suggesting minor pre-existing virus was amplified (44). Recent 
studies showed that although such mutations may produce 
an escape resistance to an HIV-specific bNAb, treatment of 
HIV-1 infected humans with a monoclonal antibody transiently 
reduced viral loads (14, 15). In a follow on study, it was shown 
that after treatment with a MAb, patient serum displayed 
enhanced neutralizing breadth, but the virus rebounded and 
certainly was not cleared (14). As  we  know, “people don’t 
FiGURe 2 | Schematics of engineered antibodies for anti-Hiv-1 investigations.
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make monoclonal antibodies” when they are infected with a 
pathogen. In other words, using polyclonal antibodies, several 
mAbs in combination or a bsAb can imitate the methods by 
which immunoglobulins in vivo clear or block pathogens. Thus, 
strategies of using several bNAbs in combination, and especially 
of using the synergistic antiviral activity of bispecific antibodies 
against HIV-1 have been explored in order to confront the 
emergence of resistant mutants.
Novel antibody-engineering technologies have led to the gen-
eration of antibodies with amounts of different shapes and sizes, 
including bispecific and multi-antibodies. The bsAb against two 
targets represents one of the promising new-generation antiviral 
therapeutic antibodies. This type of antibody targets two differ-
ent antigens or epitopes on the pathogen with different inhibi-
tory actions, or could link cells to create an immune response 
(Figure 2). Generally, it is designed in accordance with several 
main criteria: (A) the candidate mAbs should process an antiviral 
breadth attacking distinct epitopes and non-overlapping; (B) the 
candidate mAbs should not compete with each other for antigen 
binding; (C) if possible, resistant HIV-1 mutants picked from 
one mAb would be neutralized by another non-selecting mAb; 
(D) selected antibody should exhibit bivalent binding against the 
virion, and with a special geometry that overcomes the low con-
centration of spikes on the HIV-1 surface; (E) the fused antibody 
should be of low immunogenicity; and (F) the antibody should be 
able to be purified simply by affinity for a protein A/G or by other 
chromatographic methods.
Currently, various bsAb versions, such as IgG-like bispecific 
antibody (IgG-scFv) and dual variable domain immunoglobulin 
(DVD), have been designed and generated (45, 46). The IgG-scFv 
is usually designed and expressed by fusing another antibody’s 
scFv to the heavy chain of IgG’s C or N-terminus via a flexible 
GS linker peptide; this bsAb keeps the original IgG constant 
domains intact, and, thus, exhibits crystallizable fragment (Fc)-
mediated activities. CrossMab is also an IgG-scFv generated by 
the association of the heavy chains using the “knobs into holes” 
(KIH) approach; this approach is based on single amino acid 
residue substitutions in the opposite CH3 domains, and thereby 
promotes heavy chain heterodimerization (47, 48). In one of the 
heavy chains referred to as a “knob” variant, a small amino acid 
residue is replaced with a larger one (T366Y), and, in the other 
CH3 domain, a large amino acid residue is replaced with a smaller 
one (Y407T). It provides different heavy chain interaction with 
the “knobs” variant mimicking a key-lock concept. As a bsAb, 
CrossMab is a monovalent antibody format but is less immuno-
genic compared with IgG fusion bsAb.
In 2013, Pace et al. created IgG-like bispecific Abs that com-
bined inhibition of the attachment of HIV-1 virus to the host cell 
surface by a mAb directed against CD4, with that of anti-gp120 
with two copies of pG9 scFV; these antibodies exhibited potency 
and breadth, neutralizing most of the 118 HIV-1 strains tested 
at very low antibody concentrations (49). Another type of bsAb 
combines CD4 and CD4i antibodies, and also functioned against 
HIV-1 in several studies. It is a fusion protein of domains 1 and 2 
(D1D2) of soluble CD4 (sCD4) with 17b, and it exhibited broader 
and more potent activity than did b12, 4E10, and 2G12 in many 
neutralizing HIV-1 strains (50).
CrossMab of PRO140/10E8 and iMab/10E8 are designed 
based on different neutralization mechanisms, one of which 
involves inhibition of virus attachment to CD4/CCR5 of the host 
cell surface; the other in a pre-fusion neutralization manner. 
It also improves the antiviral activity significantly at a potency 
about 20-fold higher than that of the parent antibody by anchor-
ing 10E8 at the site of viral entry into host cell, enhancing both the 
local antibodies’ concentration and accessibility to their cognate 
epitope (51). Notably, the activities of the PRO140/PGT128 and 
PRO140/117 crossMabs do not compare with that of the parent 
antibody due to monovalent binding. The Bill and Melinda Gates 
Foundation Collaboration for AIDS Vaccine Discovery (BMGF 
CAVD) has now selected this crossMab formatted bispecific IgG 
for the new generation of preventive and therapeutic candidates 
for HIV/AIDS.
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variable Region Modification
Although the variable region is responsible for the antigen-
binding properties of neutralizing antibodies, it can also affect 
their immunogenicity. It has been noted that antiviral activity of 
one of the broadly neutralizing HIV-1 antibodies, NIH45–46, was 
improved significantly by introducing a G54W mutation into the 
CDR2 in the heavy chain variable region using structure-based 
design (52). Since the CD4-binding site of gp120 is a vital target 
and recognized by NIH45–46, random modification of the 
CDRH2 of antibody might, even though slightly, increase the 
binding energy between the bNAb and gp120, and subsequently 
destroy the interaction between antibody and antigen, leading to 
loss of bNAb antiviral activity. However, in this case, structure-
based design approaches to rationally modify the residues of 
the NIH45–46 heavy chain variable region that contact gp120 
partly mimic approaches to mAb affinity maturation and sim-
plify the procedure of maturation without a relative change in 
immunogenicity.
Recently, Song et  al. improved one neutralizing mAb’s 
inhibition of HIV-1 viral activity by carrying out a strategic 
and specific glycosylation of the antibody (53). In this study, 
based on activity of ibalizumab against 118 HIV-1 strains 
and structural modeling, a 9mer glycan on the N-terminus of 
gp120 fills a vacant space between the L chain’s variable region 
of ibalizumab and gp120 V5. Therefore, potential N-linked 
glycosylation sites at various positions in the L chain were 
created in this mAb. One particular mutant (LM52) neutralized 
almost 100% of the tested 118 HIV-1strains at potency more 
than 10-fold higher than that of the parental antibody. Indeed, 
strategically adding a glycan into the antibody is more reason-
able than introducing an artificial loop with a different length 
because glycan is typically non-immunogenic compared with 
protein. Besides, all modifications focused on a position of the 
light chain close to gp120 V5, and engineered glycosylation of 
the antibody minimizes the influence of the interaction between 
light chain and gp120.
Engineering efforts are also currently aimed at modifying 
antibody constant regions since neutralizing antibodies can also 
exert anti-HIV-1 effects, such as antibody-dependent cellular 
cytotoxicity (ADCC) and antibody-dependent cell-mediated 
virus inhibition (ADCVI), using the Fc portion of the full-length 
antibody (54–56).
Broadly Neutralizing Antibody  
Delivery In Vivo
Although several broad and potent neutralizing antibodies 
have been isolated recently, an unresolved key issue is why only 
certain infected patients produce bNAbs against HIV-1. One of 
the explanations is that the ability to generate bNAbs is deter-
mined by host genetic factors, but there are not enough studies 
to support this hypothesis. Since it is still a challenge to elicit 
immune response in vivo against HIV isolates, passive infusion 
or antibody gene delivery might be of use. However, passive infu-
sion also has several shortcomings, particularly in a prophylactic 
setting. These mAbs have a limited life span, and they need to 
be injected repeatedly over a long period of time, and repeated 
dosing carries a risk of injection-associated infection (57, 58). 
Thus, passive infusion as a prevention regimen on a large scale 
is impractical.
Gene transfer, one potential approach to overcome such 
limitations, requires the development of efficient and non-toxic 
polynucleotide delivery mechanisms (59–61). Muscle cells are 
capable of synthesizing, secreting, and generating a properly 
folded antibody; hence, antibody gene transfer via electroporation 
(EP) into muscle cells has great potential in terms of therapeutic 
applications (62, 63). Remarkably, the antibody concentration 
obtained in  vivo in our studies is at least 10-fold higher than 
what is required to neutralize a large panel of viruses up to 100% 
efficiency by novel engineered Abs (64).
Vector-mediated gene transfer could be used to engineer 
secretion of broadly neutralizing antibodies in vivo. Johnson et al. 
have successfully used a gene transfer approach to produce in vivo 
an SIV-neutralizing monoclonal antibody by intramuscular (IM) 
injection of a recombinant adeno-associated virus (rAAV) vector 
carrying the bNAb gene (65). Notably, the antibody concentra-
tions measured in the serum were well above the IC50 required 
for SIV neutralization for many months after inoculation. Most 
importantly, these monkeys were also protected from SIV 
infection (66). Meanwhile, the eCD4–IgG studies also display 
remarkable protection against SHIV challenge in macaques by 
AAV-expressed eCD4–Ig (67).
The use of AAV-based vectors has been reported to result in 
long-lived expression of full-length human antibodies in muscle 
after a single intramuscular injection that could fully protect 
humanized mice from HIV infection (13). In this study, b12–IgG 
serum concentrations of 100 mg/mL in humanized mouse after 
rAAV injection could protect from HIV-1 infection at challenge 
doses 100-fold higher compared with necessary doses to infect 
the non-human primate. In 2012, the same lab provided human 
HSPCs transduced with a lentiviral construct encoding b12–IgA2 
into the humanized bone marrow-liver-thymus (BLT) mouse (68, 
69). The humanized mice with a very low b12–IgA concentration 
in plasma and mucosal sites were fully resistant to mucosal chal-
lenge with HIV-1.
Advances of engineered humoral immunity with potent neu-
tralizing anti-HIV antibodies using delivery of different antibody 
genes can effectively reduce disease progression. And these novel 
antibody delivery approaches would be even more beneficial if 
they are applied combining with those recently discovered new 
generation potent broadly neutralizing antibodies.
UNDeRSTANDiNG eNGiNeeReD Hiv-1-
NeUTRALiZiNG ANTiBODieS
For HIV-1 neutralization, there are several reasons why it is dif-
ficult to find targets for bNAbs (8, 70, 71), including (A) complex 
genetic diversity of HIV-1 clades, circulating recombinants and 
mutants; (B) that glycans of gp120 cover the neutralizing epitopes, 
which makes them inaccessible to antibodies; and (C) that HIV-1 
all strains bind to the CD4 molecule, but the CD4-binding site 
of gp120 is located in a pocket that is difficult for an antibody to 
access. Thus, optimized activities by HIV-1 neutralizing antibody 
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engineering display one of the potential approaches to solve the 
above difficulties.
In general, virus neutralization is considered to happen when 
a neutralizing antibody occupies the adequate epitopes on the 
viral surface. This “occupancy” model, also known as the “multi-
hit model,” indicates that, when neutralizing antibodies achieve 
enough binding density on a virion, it will result in inhibition of 
attachment to cellular receptors or fusion processes (72). Here, 
engineering the antigen-binding properties of neutralizing anti-
bodies provide better inhibitory activity with the “critical binding 
site” model compare with “multi-hit” model. High affinity/speci-
ficity modification, the potent neutralization is determined by its 
targeting of vital binding sites and be less dependent on achieving 
high antibody densities against HIV-1. Moreover, engineering 
antibodies may enable these optimized potent antibodies to be 
delivered at a lower dose with less frequency in vivo.
In terms of synergistic antiviral activity of bispecific antibod-
ies, binding with higher affinity usually contributes to neutral-
izing activity of viruses expressing high densities of spikes (73). 
However, HIV-1 has a limited number of spikes and low density 
of viral trimers will cause neutralizing antibody to be less efficient 
for inhibition through interfering with bivalent binding to the 
HIV-1. Mature HIV-1 particles express only 10–15 randomly dis-
tributed viral spikes, and the spikes are, thus, spaced too far apart 
to be bridged by a bivalent antibody (73, 74), suggesting that only 
the special geometry of a bsAb can overcome the low density of 
spikes on HIV-1. Thus, bivalent binding needs rational design to 
generate heterotypic bivalent (bispecific) binding for HIV-1, such 
as pro140/10E8 CrossMab. In a word, dual conserved targets of 
bispecific antibodies diminish the importance of steric hindrance 
to access the tight crypt during viral entry into cells. The bispecific 
antibodies also mediate the cross-linking of virions that, when 
combined with greater activity, results in inhibiting HIV-1 entry 
into host cells.
For variable region modification, the targeted mutagenesis 
approach utilizes site-directed mutagenesis against the functional 
contact region to generate limited collections of the specific 
variants of the parent antibody. Screening based on divergent 
HIV-1 Envs could reduce the cross-reactivity to other antigens, 
broaden the specificity to HIV-1 cognate antigens, overcome 
genetic diversity of HIV-1, and substantially enhance its inhibi-
tory activity. Meanwhile, the effect of glycan has been studied, 
and it was found that Fc bearing fucosylated and sialylated 
glycans have reduced affinities for FcRs (75). It has been reported 
that an N-linked carbohydrate specific introduction into IgG’s 
variable region caused optimized solubility (76, 77). Optimized 
placement of glycan in the antibody variable region, using the 
steric hindrance against viral entry strategy, markedly improves 
the antibody’s activity. Indeed, the precise and proper glycan-
addition approach may be applied to enhance other bNAbs’ 
functional activity against HIV-1. As a potential alternative 
approach, HIV-1 antibody gene delivery technology provides the 
possibility of high density that antibodies bind to virion through 
relative stable and persistent expression, resulting in protection 
against HIV-1 mucosal infection.
HIV-1 presents special hurdles to producing neutralizing anti-
bodies with high potency and breadth. In order to successfully 
defend against HIV-1, extensive strategies may be required to 
generate “the better” antibody against virus by applying multiple 
novel antibody engineering technologies. Variable region tech-
nologies, bsAb generation, and antibody delivery would appear 
to be essential technologies for developing next-generation 
antibody therapeutics to enhance the magic bullet with radiation 
against HIV-1.
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